Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

This "news feature" in the August issue of Nature

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154912
(Total Views: 952)
Posted On: 09/05/2021 1:43:53 PM
Posted By: Borel Fields
This "news feature" in the August issue of Nature Biotechnology on "Covid-19 Long Haulers" is more than a "nice mention" of leronlimab. Despite the FDA letter, this shows CytoDyn - even in Covid - can be discussed in the nicest of nice company. (A link to this was posted earlier.)

Along with being included in a table of only 7 drugs in long-hauler clinical trials, and Kelly being quoted saying the virus could enter human brains by traveling along the olfactory nerve, below is the main section on CytoDyn. Particularly note their positive phrasing about CD-12 results and note on CCR5 MOAs in general.

While slightly disappointing that this was written before the LH Phase 2 was finished, it indicates they will have interest.

"On the US West Coast, CytoDyn is testing its CC-motif chemokine receptor 5 (CCR5) antagonist leronlimab, ..., in a phase 2 trial with a target enrollment of 50 people. CCR5 is implicated in many disease processes, including HIV, multiple sclerosis and metastatic cancer.

CytoDyn’s marketing materials claim it helps to modulate immune cell trafficking to sites of inflammation. Leronlimab has already been tested in a phase 2b/3 clinical trial as add-on therapy for respiratory illness in patients critically ill with COVID-19. Results showed a survival benefit compared with commonly used treatments, and the current phase 2 will investigate the drug as treatment for wide-ranging symptoms.

In explaining the rationale for using leronlimab in long-COVID, Kelly says that CCR5 binding will help to regulate the immune response, so that macrophages and other immune cells “don’t rush in all at once and destroy tissue. We think we can coordinate immune tracking to slow inflammation.”"

https://www.nature.com/articles/s41587-021-00...Dba8z9hDjM


(20)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us